CIK 0002028614 · <br>Emerging growth company
Drugs Made In America Acquisition Corp.
Sign in to watch- Ticker
- DMAA
- Exchange
- Nasdaq
- Industry
- Blank Checks
- FY end
- Dec 31
- Entity type
- operating
- Phone
- 646-726-7074
- Business address
- 420 LEXINGTON AVENUE, SUITE 1402, NEW YORK, NY, 10170
Securities
- DMAA Ordinary Shares Nasdaq
- DMAAR Rights Nasdaq
- DMAAU Units Nasdaq
- 10-K Report Annual Report
- SCHEDULE 13D Stake Beneficial Ownership Report
- 8-K Event Unregistered share sale · Other events
- 8-K Event Other events
- 4 Open-market buy 10% owner bought 30,000 shares
- 4 Open-market buy CEO and Exe. Chair of Board bought 30,000 shares
- 4 Open-market buy 10% owner bought 400,000 shares
- 4 Open-market buy CEO and Executive COB bought 400,000 shares
- 8-K Event Other events
- 4 Other acquisition Director acquired 100,000 shares (other)
- 4 Other acquisition Director acquired 100,000 shares (other)
- 4 Other acquisition Director acquired 100,000 shares (other)
- 4 Other acquisition CFO acquired 100,000 shares (other)
- 8-K Event Material agreement · Unregistered share sale · Bylaws or fiscal year change · Other events
- 424B4 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- CORRESP Other Correspondence Between Filers and SEC Staff
- POS AM Other Post-effective Amendment for Registration Statement
- POS AM Other Post-effective Amendment for Registration Statement
Page 3 of 4 · 80 filings